Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer

Overview

No medication existed for BQ dependence. No clinical trials existed for the drug therapy. Previous study showed that BQ possessed the antidepressant effect via pathway of monoamine oxidase A (MAO-A). An animal model also found that the arecoline from BQ has a property as MAO-A inhibitor. Therefore, the investigators hypothesized that inhibition of the MAO-A or antidepressants might reduce the BQ addiction severity. The investigators will conduct the randomization and double blinded with placebo controlled study with 90 participants with BQ dependence from the Family Medicine and ear, nose, and throat (ENT) outpatient department (OPD). All participants shall agree the informed consent. The range of age is from 18 to 65 years old. The participants are diagnosed as BQ use disorder without other psychiatry co-morbidity, according to the Diagnostic and Statistical Manual (DSM)-V criteria. Those who have severe physical illness, psychiatric illness, and other substance use disorder except cigarettes are excluded. All participants receive the semi-structure interview by DSM-V, International Classification of Diseases (ICD)-10, and Mini International Neuropsychiatric Interview by the psychiatrist. Before the intervention, the participants will finish their basic data, daily amount of cigarettes, betel nut, medical history and psycho-social rating scales. Next, in addition to counseling, the investigators will continue or modify the optimal antidepressants based on the previous results. The investigators will evaluate their BQ use condition as what has been measured in the natural observation study of the first year. The investigators will check the outcome measurement by visual analog scale, betel quid withdrawal severity scale, Yale-Brown Obsessive-Compulsive (Y-BOCS) – betel quid (BQ) scale. The investigators also followed their hamilton depression scale; Beck depression index; and Beck anxiety index in the baseline, 2nd, 4th, 6th , and 8th week. The investigators also obtained the participants' gene type if the participants also agree for the prediction of oral cancers.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 31, 2018

Detailed Description

We'll conduct the betel-quid (BQ) dependence clinical trial since 2016. Eligible cases will be enrolled for the following 8 week double-blinded placebo controlled trial. The groups will be divided into three groups. Outcome measures include BQ use condition, addiction severity rating scale, emotional rating scale including Beck Anxiety Index (BAI), Beck Depression Index (BDI), Hamilton Depression Scales (HAMDs), and urine BQ metabolites.

Interventions

  • Drug: escitalopram
    • antidepressant use for the betel-quid abstinence
  • Drug: Moclobemide
    • antidepressant use for the betel-quid abstinence
  • Drug: Placebo – Cap
    • Placebo – Cap

Arms, Groups and Cohorts

  • Experimental: medication pills 1: escitalopram 10mg
    • 10mg once daily, 8 weeks
  • Experimental: medication pills 2: moclobemide 150mg
    • 150mg once daily, 8 weeks
  • Experimental: medication pills 3: Placebo – Cap
    • placebo once daily, 8 weeks

Clinical Trial Outcome Measures

Primary Measures

  • betelnut use severity rating scale for addiction severity of betelnut
    • Time Frame: 8 weeks
    • The betelnut severity rating scale is a questionnaire rated by the psychiatrist or trained psychologist/nurse, containing 21 yes or no questions about betelnut use

Secondary Measures

  • Hamilton Depression Rating Scale for depression
    • Time Frame: 8 weeks
    • for depression
  • Beck depression index, copyrighted in Chinese (The Psychological Cooperation, Harcourt Brace& Company)
    • Time Frame: 8 weeks
    • self-rating for depression
  • Beck anxiety index, copyrighted in Chinese (The Psychological Cooperation, Harcourt Brace& Company)
    • Time Frame: 8 weeks
    • self-rating for anxiety
  • betelnut use Yale-Brown Obsessive Compulsive Disorder-like Scale for the craving status
    • Time Frame: 8 weeks
    • Yale-Brown Obsessive Compulsive Disorder-like Scale, translated in Chinese and betelnut use craving form, a questionnaires containing 10 questions rated by the psychiatrist or trained psychologist/nurse, severity from 0-4
  • betelnut metabolites urinary analysis
    • Time Frame: 8 weeks
    • arecoline, arecaidine, and N-methylnipecotic acid checked by liquid chromatography mass spectrometry (LC-MS)

Participating in This Clinical Trial

Inclusion Criteria

  • DSM-V criteria suitable for betelnut use disorder – No severe physical disorder – No major psychiatric illness – Chinese Speaker Exclusion Criteria:

  • Severe physical disorder – Major psychiatric illness – Inability to understand the whole protocol

Gender Eligibility: Male

Minimum Age: 14 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • China Medical University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ko Ying-Chin, PHD, Study Director, China Medical University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.